ArticleClinicoEconomics and outcomes research : CEOR2023

Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States.

Lita Araujo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.